

STUDY ACTIVATION PROJECT PLAN

MAGGIE LINDENBAUM

DIRECTOR, COORDINATION SERVICES & EDUCATION
STUDY ACTIVATION TEAM

UCLA | OFFICE OF CLINICAL RESEARCH


CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE

Common Questions from Investigators

- How do I **identify** all of the study activation steps?
- How do I **track** the study activation process and stay on target?
- How can I **minimize hurdles** to study activation?
- Patients are waiting. When can I **start screening**?




Study Activation: Industry-Authored Clinical Trial



Illustrative Purposes Only – activation process not sequential

Study Activation when there is no transparency



Study Activation Key Considerations

- Identify Steps
- Track Progress
- Minimize Hurdles
- Project Open to Enrollment Date




Study Activation Progress Plan - General

IDENTIFY

Project Plan General



IRB #:	12-001234
Sponsor:	Enterprise
Protocol #:	NCC1701
PI:	Picard
Short Title:	Enterprise NCC1701 Irumodic Syndrome
Last update:	7/11/18



Study Activation Progress Plan - Report

Study Activation Progress Report



IRB #: 12-001234
Sponsor: Enterprise
Protocol #: NCC1701
PI: Picard
Short Title: Enterprise NCC1701 Intradomic Syndrome

Target IRB Submission:	2/1/18		
Target Open Enrollment:	5/3/18	13.0	wks
Full Regulatory Packet:	1/1/18		
Actual IRB Submission:	3/1/18		
Projected Open Enrollment:	6/11/18	18.6	wks
Legend			
RA: Review and Approval			
P: Process		Actual Data from OnCore	
D: Document		Manual Entry	
ST: Study Team		Has Dependencies	

Instructions: Update the light blue cells in the dark blue columns as tasks are started, submitted and completed/approved to track study activation progress in real time. The grey cells are automatically updated to reflect the current data imported into the oncore tab.

Study Startup Tasks			Target Dates		Actual Dates based on OnCore Data		Task Progress					Target Turnaround		Actual Turnaround		Responsibility Matrix and Resources								
Milestone #	Task Type	Description	Start Date (Submission Date)	Completion Date (Approval Date)	Start Date (Submission Date)	Completion Date (Approval Date)	Not Initiated	In progress	Completed	Overall	PI Action Required	Note	Target Turnaround	Actual Turnaround	Delta	Responsible for Task Start	Task Started When	Task Completed when:	Study Team Contact	Study Team Contribution (Tips and Best Practices)	UCLA Office Acronym	UCLA Office Full Name	UCLA Office Contact (email address and website)	Note
		IRB and Committee Approvals	Submit to ancillaries within 1 wk of IRB																					
25	RA	New Study IRB Approval	2/1/18	5/24/18	3/1/18	3/28/18		x	✓				16 weeks	4 weeks	-8	Study Team	Submission of New	IRB issues approval notice	name of	Respond to IRB	CHRRP	Office of Human	Owner (IRB Staff) named on	
26	RA	Internal Scientific Review Approval	2/4/18	3/4/18	1/26/18	2/23/18		x	✓				4 weeks	4 weeks	-1	Study Team	SRC will email if	SRC issues approval notice	name of	Respond to SRC	CTSI SRC (non-	Scientific Review	ctsisrc@mednet.ucla.edu	
27	RA	Medical Radiation Safety Approval	2/4/18	3/4/18	3/1/18	2/23/18		x	✓				4 weeks	-1 weeks	-1	Study Team	Section 8.11	MRSC issues approval	name of	Connect with	MRSC	Medical Radiation	mrrsc@mednet.ucla.edu	
27	RA	Conflict of Interest Review Approval	2/4/18	3/4/18	1/26/18	2/23/18		x	✓				4 weeks	4 weeks	-1	Study Team	Submission of	CIRC issues letter with final	name of	CIRC meets once a	CIRC	Conflict of Interest	circ@mednet.ucla.edu	
27	RA	Institutional Biosafety Approval	2/4/18	3/18/18	1/26/18	3/9/18		x	✓				6 weeks	6 weeks	-1	Study Team	Submission of new	IBC issues approval notice	name of	Send blank IBC	IBC	Institutional Bio	ibc@mednet.ucla.edu	
27	RA	Embryonic Stem Cell Research Oversight	2/4/18	3/18/18	1/26/18	3/9/18		x	✓				6 weeks	6 weeks	-1	Study Team	Submission of	ESCRO issues approval	name of	Confirm with ESCRO if	ESCRO	Embryonic Stem	escro@mednet.ucla.edu	
27	RA	Value Analysis Approval	2/4/18	3/4/18	1/26/18	2/23/18		x	✓				4 weeks	4 weeks	-1	Study Team	Submission of	VAC issues approval notice	name of	Required if	VAC	Value Analysis Co	vac@mednet.ucla.edu	
27	RA	Clinical Engineering Approval or Acceptance	2/4/18	3/4/18	1/26/18	2/23/18		x	✓				4 weeks	4 weeks	-1	Study Team	Email summary of	Clinical Engineering issues	name of		CE	Clinical Engineer	cemilian@mednet.ucla.edu	

IDENTIFY

TRACK

MINIMIZE HURDLES

Study Activation Progress Plan - Report

IDENTIFY STEPS

Study Startup Tasks			Target Dates	
			Start Date (Submission Date)	Completion Date (Approval Date)
Milestone #	Task Type	Description		
		IRB and Committee Approvals	Submit to ancillaries within 1 wk of IRB	
25	RA	New Study IRB Approval	2/1/18	5/24/18
26	RA	Internal Scientific Review Approval	2/4/18	3/4/18
27	RA	Medical Radiation Safety Approval	2/4/18	3/4/18
27	RA	Conflict of Interest Review Approval	2/4/18	3/4/18
27	RA	Institutional Biosafety Approval	2/4/18	3/18/18
27	RA	Embryonic Stem Cell Research Oversight	2/4/18	3/18/18
27	RA	Value Analysis Approval	2/4/18	3/4/18
27	RA	Clinical Engineering Approval or Acceptance	2/4/18	3/4/18

Study Activation Progress Report



IRB #:	12-001234
Sponsor:	Enterprise
Protocol #:	NCC1701
PI:	Picard
Short Title:	Enterprise NCC1701 Inimodic Syndrome

Instructions: Update the light blue cells in the dark blue columns as tasks are started, submitted and completed/approved to track study activation progress in real time. The grey cells are automatically updated to reflect the current data imported into the oncore tab.

Study Activation Progress Plan - Report

TRACK
PROGRESS

Target IRB Submission:	2/1/18			
Target Open Enrollment:	5/3/18	13.0	wks	
Full Regulatory Packet:	1/1/18			
Actual IRB Submission:	3/1/18			
Projected Open Enrollment:	6/11/18	18.6	wks	
Legend				
RA: Review and Approval				
F: Process	Actual Data from OnCore			
D: Document	Manual Entry			
ST: Study Team	Has Dependencies			

Actual Dates based on OnCore Data		Task Progress						Target Turnaround		Actual Turnaround		
Start Date (Submission Date)	Completion Date (Approval Date)	Not Initiated	In progress	Completed	Overall	PI Action Required	Note	Target Turnaround	Actual Turnaround	±		
3/1/18	3/28/18			x	✓			16 weeks	4 weeks	-8		
1/26/18	2/23/18			x	✓			4 weeks	4 weeks	-1		
3/1/18	2/23/18			x	✓			4 weeks	-1 weeks	-1		
1/26/18	2/23/18			x	✓			4 weeks	4 weeks	-1		
1/26/18	3/9/18			x	✓			6 weeks	6 weeks	-1		
1/26/18	3/9/18			x	✓			6 weeks	6 weeks	-1		
1/26/18	2/23/18			x	✓			4 weeks	4 weeks	-1		
1/26/18	2/23/18			x	✓			4 weeks	4 weeks	-1		


Study Activation Progress Plan - Report

MINIMIZE
HURDLES

Responsibility Matrix and Resources

Responsible For Task Start	Task Started When	Task Completed when:	Study Team Contact	Study Team Contribution (Tips and Best Practices)	UCLA Office Acronym	UCLA Office Full Name	UCLA Office Contact (email address and website)	Note
Study Team vs. UCLA Office								
Study Team	Submission of New	IRB issues approval notice	name of	Respond to IRB	OHRPP	Office of Human	Owner (IRB Staff) named on	
Study Team	SRC will email if	SRC issues approval notice	name of	Respond to SRC	CTSI SRC (non-	Scientific Review	ctsisrc@mednet.ucla.edu	
Study Team	Section 8.11	MRSC issues approval	name of	Connect with	MRSC	Medical Radiation	mrsc@mednet.ucla.edu	
Study Team	Submission of	CIRC issues letter with final	name of	CIRC meets once a	CIRC	Conflict of Interest	circ@mednet.ucla.edu	
Study Team	Submission of new	IBC issues approval notice	name of	Send blank IBC	IBC	Institutional Bios	ibc@mednet.ucla.edu	
Study Team	Submission of	ESCRO issues approval	name of	Confirm with ESCRO if	ESCRO	Embryonic Stem c	escro@mednet.ucla.edu	
Study Team	Submission of	VAC issues approval notice	name of	Required if	VAC	Value Analysis Co	vac@mednet.ucla.edu	
Study Team	Email summary of	Clinical Engineering issues	name of		CE	Clinical Engineeri	vemilian@mednet.ucla.edu	


Study Activation Progress Plan - Report

<h2>Study Activation Progress Report</h2> <p>UCLA Study Activation Team Office of Clinical Research</p> 	IRB #:	12-001234	Target IRB Submission:	2/1/18		
	Sponsor:	Enterprise	Target Open Enrollment:	5/3/18	13.0	wks
	Protocol #:	NCC1701	Full Regulatory Packet:	1/1/18		
	PI:	Picard	Actual IRB Submission:	2/1/18		
	Short Title:	Enterprise NCC1701 Irumodic Syndrome	Projected Open Enrollment:	6/11/18	18.6	wks

Project Open to Enrollment Date

Study Activation in 90 Calendar Days

★ From IRB Submission to Open to Accrual



Further Development

1. Development phase: Define turn around times for all tasks
2. Testing phase: test functionality using expected cases
3. Pilot phase: track startup timelines of real studies
4. Use project plan to inform dashboards and analytics
5. Align with questionnaire to enable self-service Project Plans
6. Adapt to other workflows
 - HemOnc
 - IRB Reliance
 - Investigator Initiated Studies

THANK YOU

UCLA | OFFICE OF CLINICAL RESEARCH

CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE